Compugen Ltd. (CGEN) Company Overview

What does Compugen do?

Compugen Ltd. is an Israel-based clinical-stage biotechnology company focused on cancer immunotherapy. Its central capability is Unigen™, a computational discovery platform that combines proprietary biological datasets, predictive models, and experimental validation to identify drug targets that may be difficult to find through conventional screening. The company then turns selected targets into therapeutic antibodies, advances some programs internally, and licenses others to larger pharmaceutical partners.

The four clinical-stage programs are COM701, COM902, rilvegostomig, and GS-0321. COM701 is Compugen’s wholly owned lead program and targets PVRIG, an immune checkpoint discovered by the company. COM902 targets TIGIT. Rilvegostomig is an AstraZeneca-developed PD-1/TIGIT bispecific whose TIGIT component is derived from COM902. GS-0321, formerly COM503, targets IL-18 binding protein and is licensed to Gilead. The official clinical-trials overview shows how the internal and partnered programs now sit at different development stages.

How does Compugen make money?

Compugen’s revenue model is collaboration-driven rather than volume-driven. The company seeks upfront license payments, funded development work, milestone payments, and royalties from partners that can finance late-stage trials and commercialization. Revenue can therefore be large in one period and modest in the next, depending on contract amendments, clinical events, and accounting recognition under ASC 606.

Which programs carry the economic model?

How do discovery rights become cash?

The two major agreements have different scales. The 2025 Form 20-F reports up to approximately $758 million of additional Gilead milestones and up to $195 million of remaining AstraZeneca regulatory and commercial milestones after the December 2025 royalty transaction.

Which pipeline assets matter most?

Why is COM701 the central company-controlled catalyst?

COM701 is the clearest test of whether Compugen can independently translate a computationally discovered target into clinically meaningful benefit. The company argues that PVRIG biology may be particularly relevant in less inflamed tumors, including ovarian cancer, because of the expression of PVRIG on stem-like memory T cells and PVRL2 on dendritic and tumor cells. That thesis still requires randomized clinical validation.

Why does rilvegostomig matter even though Compugen does not control development?

Rilvegostomig gives Compugen exposure to a broad late-stage program run by a global pharmaceutical company. The company retained most of its royalty interest after selling a portion to AstraZeneca for $65 million in December 2025, and it remains eligible for tiered royalties up to the mid-single digits. The asset therefore combines non-dilutive funding today with contingent participation in future approvals and sales. The trade-off is dependence: trial design, spending, prioritization, regulatory strategy, and commercialization are controlled by AstraZeneca, not Compugen.

What turning points shaped Compugen’s current strategy?

Compugen’s history is a transition from computational biology to immuno-oncology and then to a hybrid portfolio of wholly owned and partnered assets.

1. 1993
   Compugen was incorporated in Israel, creating the institutional base for a computational approach to biological discovery.
2. 2002
   The shares became dually listed on the Tel Aviv Stock Exchange, complementing the U.S. Nasdaq listing and broadening market access.
3. 2018
   Compugen licensed COM902-derived bispecific and multispecific rights to AstraZeneca and dosed the first COM701 Phase 1 patient, linking discovery IP to clinical development.
4. 2022
   The Bristol Myers Squibb clinical collaboration ended, forcing a sharper portfolio and partnership reset.
5. 2023
   The Gilead license for the IL-18BP program established a second major pharmaceutical partnership and a new source of upfront and milestone economics.
6. 2025
   Compugen initiated MAIA-ovarian, transitioned Eran Ophir to President and CEO and Anat Cohen-Dayag to Executive Chair, and monetized part of the rilvegostomig royalty for $65 million.
7. 2026
   Q1 execution centered on enrolling MAIA-ovarian, advancing GS-0321 Phase 1, and preserving cash runway into 2029 ahead of major clinical readouts.

What did the 2025 royalty monetization change?

The transaction changed the balance-sheet risk more than the operating model. Compugen received immediate non-dilutive capital, added $25 million to the next potential milestone tied to first BLA acceptance, retained the majority of future royalties, and extended expected runway. However, the $65 million payment also made FY2025 revenue and profit unusually high; it should not be treated as evidence of a recurring commercial earnings base.

What did the leadership transition signal?

Eran Ophir’s move from Chief Scientific Officer to President and CEO preserved scientific continuity while placing operating execution under a new chief executive. Anat Cohen-Dayag’s move to Executive Chair retained institutional knowledge and strategic influence. The current leadership roster also identifies David Silberman as CFO and Michelle Mahler as Chief Medical Officer, emphasizing the financial and clinical capabilities needed for the next phase.

What does the latest quarter show?

The Q1 2026 results show a return to the normal economics of a clinical-stage biotech after the one-time-heavy FY2025 period. Revenue was $2.176 million, largely reflecting recognition associated with the Gilead agreement. R&D increased as MAIA-ovarian enrollment and clinical drug-supply activity expanded.

How financially strong is Compugen?

Compugen’s near-term financial strength comes from liquidity rather than recurring profitability. At March 31, 2026, cash, short-term bank deposits, and marketable securities totaled approximately $134.9 million. Current assets were $137.3 million against $22.0 million of current liabilities, and the company reported no debt. That creates a substantial working-capital cushion for planned clinical spending.

What explains the FY2025 profit?

How is the cash pool invested?

What gives Compugen a competitive advantage?

Compugen’s claimed advantage is not scale, manufacturing, or commercial distribution. It is the ability to discover biologically differentiated targets and convert them into defensible therapeutic programs before larger competitors. PVRIG, TIGIT, and IL-18BP are evidence that the platform has produced targets that reached human trials through Compugen or partners.

Where is the moat strongest?

The strongest proof is partner validation. AstraZeneca has moved rilvegostomig into a broad Phase 3 program, and Gilead paid $60 million upfront plus a $30 million IND milestone under the GS-0321 agreement. Those decisions show that major partners found enough potential to commit capital. Compugen also has patent protection around PVRIG-related methods and antibodies, although patent scope and opposition proceedings remain material risks.

Who competes with Compugen?

Who owns Compugen stock, and how is it governed?

Compugen has a single class of ordinary shares, with one vote per share. Its 2025 annual report states that, as of February 20, 2026, the company was not aware of any beneficial owner holding more than 5% of outstanding shares. That indicates dispersed ownership rather than founder, family, or sponsor control.

The 2025 proxy statement proposed seven directors and described five of the nominees as independent under Nasdaq rules, with the CEO and Executive Chair as the two non-independent nominees. Michele Holcomb joined as an additional independent director in February 2026. The company is also subject to Israeli corporate law and foreign-private-issuer governance provisions, which makes board composition, shareholder approvals, and committee independence particularly relevant.

How does capital allocation affect shareholders?

Compugen has never paid a cash dividend and intends to retain capital for the business. It also uses equity financing when needed: in FY2025 it sold 4.862 million ordinary shares through its at-the-market program for $10.5 million of net proceeds. The core allocation decision is therefore whether to spend cash on wholly owned clinical programs, preserve runway, or monetize portions of partner economics. Each choice changes future upside, dilution, and execution risk.

What opportunities and risks could change the story?

Compugen’s opportunity set is concentrated in a small number of high-impact events. That concentration creates downside if trials disappoint or partners reprioritize. The Q1 2026 corporate update identifies MAIA-ovarian, rilvegostomig, GS-0321, and new Unigen-derived programs as the main strategic priorities.

Which risk is most important?

Clinical efficacy risk dominates. Compugen can manage cash, choose trial pacing, and negotiate contracts, but it cannot manufacture a positive randomized outcome. Preliminary response signals do not guarantee that COM701 will improve progression-free survival, and even positive data may require additional studies before approval or commercialization. Partner programs face the same biological uncertainty at larger scale.

Where is the asymmetric opportunity?

The asymmetric opportunity comes from having multiple externally financed shots on goal while retaining a wholly owned lead asset. AstraZeneca and Gilead absorb much of the later-stage capital burden, while Compugen’s debt-free balance sheet supports COM701 and early discovery. If one partnered program succeeds and COM701 produces persuasive evidence, the company could combine royalty-like cash flows with improved bargaining power for future targets.

Which KPIs matter most for Compugen valuation?

A conventional DCF based on smooth revenue growth is poorly suited to Compugen. Valuation should be probability-adjusted and asset-specific, with assumptions for trial success, milestone timing, royalties, launch dates, cash burn, and dilution. Historical revenue is useful for understanding contract mechanics, but it is not a reliable run-rate forecast.

How should researchers build the model?

The discount rate should reflect small-cap biotechnology risk, geopolitical exposure, clinical uncertainty, and dependence on third parties. Terminal value should not assume perpetual growth from current collaboration revenue. A more defensible approach is to forecast specific milestone and royalty paths, subtract program-level development costs, and run sensitivity cases for probability of success, launch timing, peak sales, royalty percentages, and dilution.

What is the key takeaway from Compugen analysis?

Compugen matters because it offers a rare combination of computational target discovery, proprietary immuno-oncology biology, two large-pharma partnerships, and a debt-free balance sheet with several years of expected runway. The company has already shown that its platform can generate targets and antibodies that sophisticated partners are willing to finance. That is stronger evidence than a discovery platform supported only by preclinical claims.

The research case remains highly conditional. FY2025’s $72.8 million revenue and $35.3 million net profit were driven by collaboration economics, especially the $65 million AstraZeneca payment, not by sustainable product sales. Q1 2026 therefore provides the more representative operating picture: modest contract revenue, rising clinical R&D, a net loss, and substantial liquidity.